Ziwei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ziwei Chen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Junqi Wang
Department of Pediatrics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
2 shared publicationsWei Wang
Department of Pediatrics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
2 shared publicationsZhiya Dong
Department of Pediatrics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
2 shared publicationsChuanyin Li
Cancer Center, Shanghai Tenth People's Hospital, School of Medicine Tongji University Shanghai China
1 shared publication- Chuanyin Li
Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (C.L., M.Z., Y.L., R.H.).
1 shared publication Qing You
School of Biomedical Engineering, Shanghai Jiao Tong University Shanghai China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Endocrinology
- Vol. 2025 (1) , 5609749
Outcomes of Patients With Familial Central Precocious Puberty due to Mutations of MKRN3 Gene After Treatment With Gonadotropin‐Releasing Hormone Agonist
Objective: To assess the therapeutic effects of gonadotropin‐releasing hormone agonist (GnRHa) on children with familial central precocious puberty (FCPP) due to Makorin ring finger Protein 3 ( MKRN3 ) gene mutations. Methods: Children with central precocious puberty (CPP) who were admitted to the Pediatric Endocrinology Department of Shanghai Ruijin Hospital from 2014 to 2021 were enrolled, of whom 4 FCPP children with MKRN3 gene mutations, including 3 girls and 1 boy, were selected as research subjects. Their height, weight, body mass index (BMI), predicted adult height (PAH), bone age, bone age advance (BAA, bone age minus chronological age), height‐based standard deviation scores (Ht‐SDS) corresponding to the chronological age, concentrations of sex hormones (luteinizing hormone [LH] and follicle‐stimulating hormone [FSH]), and development of sexual organs were compared before and after at least 2 years of GnRHa treatment. Results: After at least 2‐year GnRHa treatment, mean volume of uterus of three girls decreased from 5.72 ± 2.58 to 2.12 ± 1.62 mL ( p < 0.05) and mean volume of ovaries decreased from 3.61 ± 1.67 to 0.62 ± 0.22 mL ( p < 0.05) as well, indicating that the gonadal development was effectively inhibited. Basal concentrations of LH and FSH in serum decreased, indicating that the secretion of gonadotropin in the anterior pituitary is inhibited. BAA and Ht‐SDS decreased, suggesting that the bone age was restrained, and the growth rate was slowed down to some extent. Both average BMI and obesity prevalence ( X 2 = 7.188, p = 0.029) decreased during the treatment. No obvious adverse reaction was found. Conclusion: Long‐term GnRHa treatment could effectively inhibit the gonadal development and FSH secretion in FCPP children with MKRN3 gene mutations, while this inhibitory effect on the bone age and growth rate was not obvious. Adverse reactions such as increased prevalence of obesity were not found. A large‐scale, long‐term follow‐up study is required to indicate whether patients’ final height (FH) could reach PAH or target height (TH).
- 1 January 2025
- Published by Wiley in International Journal of Endocrinology
- Vol. 2025 (1) , 5609749
Open AccessOutcomes of Patients With Familial Central Precocious Puberty due to Mutations of MKRN3 Gene After Treatment With Gonadotropin‐Releasing Hormone Agonist
Objective: To assess the therapeutic effects of gonadotropin‐releasing hormone agonist (GnRHa) on children with familial central precocious puberty (FCPP) due to Makorin ring finger Protein 3 ( MKRN3 ) gene mutations. Methods: Children with central precocious puberty (CPP) who were admitted to the Pediatric Endocrinology Department of Shanghai Ruijin Hospital from 2014 to 2021 were enrolled, of whom 4 FCPP children with MKRN3 gene mutations, including 3 girls and 1 boy, were selected as research subjects. Their height, weight, body mass index (BMI), predicted adult height (PAH), bone age, bone age advance (BAA, bone age minus chronological age), height‐based standard deviation scores (Ht‐SDS) corresponding to the chronological age, concentrations of sex hormones (luteinizing hormone [LH] and follicle‐stimulating hormone [FSH]), and development of sexual organs were compared before and after at least 2 years of GnRHa treatment. Results: After at least 2‐year GnRHa treatment, mean volume of uterus of three girls decreased from 5.72 ± 2.58 to 2.12 ± 1.62 mL ( p < 0.05) and mean volume of ovaries decreased from 3.61 ± 1.67 to 0.62 ± 0.22 mL ( p < 0.05) as well, indicating that the gonadal development was effectively inhibited. Basal concentrations of LH and FSH in serum decreased, indicating that the secretion of gonadotropin in the anterior pituitary is inhibited. BAA and Ht‐SDS decreased, suggesting that the bone age was restrained, and the growth rate was slowed down to some extent. Both average BMI and obesity prevalence ( X 2 = 7.188, p = 0.029) decreased during the treatment. No obvious adverse reaction was found. Conclusion: Long‐term GnRHa treatment could effectively inhibit the gonadal development and FSH secretion in FCPP children with MKRN3 gene mutations, while this inhibitory effect on the bone age and growth rate was not obvious. Adverse reactions such as increased prevalence of obesity were not found. A large‐scale, long‐term follow‐up study is required to indicate whether patients’ final height (FH) could reach PAH or target height (TH).
- 6 December 2023
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (4)
The functional study of a novel MKRN3 missense mutation associated with familial central precocious puberty
Central precocious puberty (CPP) refers to a syndrome of early puberty initiation with a characteristic increase in the release of gonadotropin‐releasing hormone (GnRH); therefore, it is also called GnRH‐related precocious puberty. About a quarter of idiopathic central precocious puberty (ICPP) may be familial. Studies suggest that mutations of makorin ring finger protein 3 (MKRN3) can cause familial central precocious puberty (FCPP). In this report, we describe a Chinese female patient carrying a novel MKRN3 variant (c.980G>A/p.Arg327His) and presenting the CPP phenotype. This novel variant attenuated its own ubiquitination, degradation, and inhibition on the transcriptional and translational activity of GNRH1, which was verified through functional tests. We can consider this variant as a loss‐of‐function mutation, which subsides the inhibition of GnRH1‐related signaling and gives rise to GnRH‐related precocious puberty.
- 6 December 2023
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (4)
The functional study of a novel MKRN3 missense mutation associated with familial central precocious puberty
Central precocious puberty (CPP) refers to a syndrome of early puberty initiation with a characteristic increase in the release of gonadotropin‐releasing hormone (GnRH); therefore, it is also called GnRH‐related precocious puberty. About a quarter of idiopathic central precocious puberty (ICPP) may be familial. Studies suggest that mutations of makorin ring finger protein 3 (MKRN3) can cause familial central precocious puberty (FCPP). In this report, we describe a Chinese female patient carrying a novel MKRN3 variant (c.980G>A/p.Arg327His) and presenting the CPP phenotype. This novel variant attenuated its own ubiquitination, degradation, and inhibition on the transcriptional and translational activity of GNRH1, which was verified through functional tests. We can consider this variant as a loss‐of‐function mutation, which subsides the inhibition of GnRH1‐related signaling and gives rise to GnRH‐related precocious puberty.